Health

Congressional Insider -   A breakthrough lung cancer treatment approved for England’s NHS nearly doubles survival for patients battling one of the deadliest forms of the disease, filling a treatment gap that has persisted for over two decades.

Approximately 530 English patients annually will benefit from the immunotherapy maintenance treatment following chemotherapy or radiotherapy. The approval represents the first advancement in limited-stage SCLC treatment in over 20 years  Treatment is immediately available through NHS following official recommendation